Baird analyst Joel Beatty raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $167 from $162 and keeps an Outperform rating on the shares. The firm noted the company has Epidiolex exclusivity into the very late 20230’s.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Positive Outlook for Jazz Pharmaceuticals: Strategic Wins and Promising Financial Projections Lead to Buy Rating
- Jazz Pharmaceuticals: Strong Financial Performance and Promising Pipeline Justify Buy Rating
- Jazz Pharmaceuticals Reports Strong 2024 Financial Results
- Jazz Pharmaceuticals reports Q4 adjusted EPS $6.60, consensus $5.81
- Jazz Pharmaceuticals sees FY25 adjusted EPS $22.50-$24.00, consensus $22.03